Wells Fargo Says Genzyme (GENZ) Guidance Eliminates Overhang; Maintains Outperform, But Lowers Estimates
Tweet Send to a Friend
Wells Fargo has lowered estimates and its valuation range on Genzyme (Nasdaq: GENZ). The firm maintains an Outperform rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
